Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours

S. Angeletti, V. D. Corleto, O. Schillaci, M. Marignani, B. Annibale, A. Moretti, G. Silecchia, F. Scopinaro, N. Basso, C. Bordi, G. Delle Fave

Research output: Contribution to journalArticle

Abstract

Background - Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. Method - The results of SRS and octreotide treatment in three somatostatinoma patients were examined. Results - SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with 'somatostatinoma syndrome'. Conclusion - The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.

Original languageEnglish
Pages (from-to)792-794
Number of pages3
JournalGut
Volume42
Issue number6
Publication statusPublished - 1998

Fingerprint

Octreotide
Somatostatinoma
Somatostatin Receptors
Somatostatin
Radionuclide Imaging
Neoplasms
Liver
Diarrhea
Therapeutics

Keywords

  • Gastroenteropancreatic endocrine tumour
  • Octreotide
  • Somatostatin
  • Somatostatin receptor scintigraphy
  • Somatostatinoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Angeletti, S., Corleto, V. D., Schillaci, O., Marignani, M., Annibale, B., Moretti, A., ... Delle Fave, G. (1998). Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours. Gut, 42(6), 792-794.

Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours. / Angeletti, S.; Corleto, V. D.; Schillaci, O.; Marignani, M.; Annibale, B.; Moretti, A.; Silecchia, G.; Scopinaro, F.; Basso, N.; Bordi, C.; Delle Fave, G.

In: Gut, Vol. 42, No. 6, 1998, p. 792-794.

Research output: Contribution to journalArticle

Angeletti, S, Corleto, VD, Schillaci, O, Marignani, M, Annibale, B, Moretti, A, Silecchia, G, Scopinaro, F, Basso, N, Bordi, C & Delle Fave, G 1998, 'Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours', Gut, vol. 42, no. 6, pp. 792-794.
Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A et al. Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours. Gut. 1998;42(6):792-794.
Angeletti, S. ; Corleto, V. D. ; Schillaci, O. ; Marignani, M. ; Annibale, B. ; Moretti, A. ; Silecchia, G. ; Scopinaro, F. ; Basso, N. ; Bordi, C. ; Delle Fave, G. / Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours. In: Gut. 1998 ; Vol. 42, No. 6. pp. 792-794.
@article{02abfac2212c4694af1c8f35b0956816,
title = "Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours",
abstract = "Background - Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. Method - The results of SRS and octreotide treatment in three somatostatinoma patients were examined. Results - SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with 'somatostatinoma syndrome'. Conclusion - The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.",
keywords = "Gastroenteropancreatic endocrine tumour, Octreotide, Somatostatin, Somatostatin receptor scintigraphy, Somatostatinoma",
author = "S. Angeletti and Corleto, {V. D.} and O. Schillaci and M. Marignani and B. Annibale and A. Moretti and G. Silecchia and F. Scopinaro and N. Basso and C. Bordi and {Delle Fave}, G.",
year = "1998",
language = "English",
volume = "42",
pages = "792--794",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Use of the somatostatin analogue octreotide localise and manage somatostatin-producing tumours

AU - Angeletti, S.

AU - Corleto, V. D.

AU - Schillaci, O.

AU - Marignani, M.

AU - Annibale, B.

AU - Moretti, A.

AU - Silecchia, G.

AU - Scopinaro, F.

AU - Basso, N.

AU - Bordi, C.

AU - Delle Fave, G.

PY - 1998

Y1 - 1998

N2 - Background - Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. Method - The results of SRS and octreotide treatment in three somatostatinoma patients were examined. Results - SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with 'somatostatinoma syndrome'. Conclusion - The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.

AB - Background - Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. Method - The results of SRS and octreotide treatment in three somatostatinoma patients were examined. Results - SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with 'somatostatinoma syndrome'. Conclusion - The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.

KW - Gastroenteropancreatic endocrine tumour

KW - Octreotide

KW - Somatostatin

KW - Somatostatin receptor scintigraphy

KW - Somatostatinoma

UR - http://www.scopus.com/inward/record.url?scp=15144358329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15144358329&partnerID=8YFLogxK

M3 - Article

C2 - 9691916

AN - SCOPUS:15144358329

VL - 42

SP - 792

EP - 794

JO - Gut

JF - Gut

SN - 0017-5749

IS - 6

ER -